

Draft Agenda

4 May

09.00	Opening Ceremony/Admin Session
09.30	TB Control in Viet Nam and the Western Pacific Region
11.00	<i>Coffee Break</i>
11.30	Responding to the Co-Epidemic: TB-HIV
12.30	<i>Lunch: Ming Palace Restaurant</i>
14.00	Accelerating the Scale Up of M/XDR-TB
15.30	<i>Coffee Break</i>
16.00	Advancing the Agenda of Diagnostics
17.00	Update of the Global Plan to Stop TB
18.30	Welcome Reception <i>hosted by the Ministry of Health, Viet Nam, Panorama Restaurant, 19th Floor, Sofitel Plaza Hotel</i>

5 May

08.30	Global Fund
09.45	TB REACH
10.45	<i>Coffee Break</i>
11.15	Strategic Session on the Future of GDF
12.45	<i>Lunch: Panorama Restaurant</i>
14.00	Drug Stock Outs
15.00	MDG Summit
16.00	<i>Coffee Break</i>
16.30	Advocacy in the US
17.30	Private Sector Constituency
18.15	Closing



TB Advocacy in the United States

Challenges, opportunities and recommendations

Rachel Wilson

Co-Chair, Advocacy Advisory Committee, Stop TB Partnership


Hanoi, 4-5 May 2010

Agenda


- **Overview of US funding for tuberculosis**
- **President Obama's Global Health Initiative**
- **Current US advocacy initiatives**
- **Recommendations for Stop TB Partnership**
- **Discussion**

Health ODA Commitments by Donor, 2001 & 2007

In Billions



Total = \$7.2 billion




Total = \$22.1 billion

Notes: Amounts in gross US\$ commitments. Health ODA combines data from four OECD CRS sub-sectors: (1) Health; (2) Population Policies/Programs and Reproductive Health (includes HIV/AIDS & STDs); (3) Water Supply/Sanitation; and (4) Other Social Infrastructure and Services - Social Mitigation of HIV/AIDS. Source: Analysis of data obtained via online query of the OECD Development Assistance Committee (DAC) Database and Creditor Reporting System (CRS), May 31, 2009.

U.S. Global Health Initiative (GHI), FY 2011 Budget Request By Sector

In Millions




Total = \$9,600 million

*FY 2011 is President's Budget Request to Congress.

Source: Kaiser Family Foundation analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and White House Statement by the President on Global Health Initiative, May 5, 2009. Also see: Kates J., *The U.S. Global Health Initiative: Overview & Budget Analysis*, Menlo Park: Kaiser Family Foundation, December 2009.

U.S. Government Funding for Global Tuberculosis (TB), FY 2001-FY 2011*

In Millions



*FY 2011 is President's Budget Request to Congress.

Note: The GHI was created as an initiative in FY 2009 and FY 2009 and FY 2010 amounts are included in its proposal; all prior years represent the same programs and accounts which were not yet referred to as the GHI.

Source: Kaiser Family Foundation analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and White House Statement by the President on Global Health Initiative, May 5, 2009.


Also see: Kates J., *The U.S. Global Health Initiative: Overview & Budget Analysis*,

Menlo Park: Kaiser Family Foundation, December 2009.



U.S. Government Funding for the Global Fund, FY 2001-FY 2011*

In Millions



FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010

**FY
2011***


*FY 2011 is President's Budget Request to Congress.

Note: The GHI was created as an initiative in FY 2009 and FY 2009 and FY 2010 amounts are included in its proposal; all prior years represent the same programs and accounts which were not yet referred to as the GHI.

Source: Kaiser Family Foundation analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and White House Statement by the President on Global Health Initiative, May 5, 2009. Also see: Kates J., *The U.S. Global Health Initiative: Overview & Budget Analysis*, Menlo Park: Kaiser Family Foundation, December 2009.



U.S. Global Health Initiative (GHI), Percent Change in Funding by Sector, FY 2010-FY 2011*




*FY 2011 is President's Budget Request to Congress.

Note: The GHI was created as an initiative in FY 2009 and FY 2009 and FY 2010 amounts are included in its proposal.

Source: Kaiser Family Foundation analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and White House Statement by the President on Global Health Initiative, May 5, 2009. Also see: Kates J., *The U.S. Global Health Initiative: Overview & Budget Analysis*, Menlo Park: Kaiser Family Foundation, December 2009.



U.S. Funding for Domestic TB



Source: American Thoracic Society



U.S. funding for TB R&D (2008 figures)

	TB	HIV	Malaria
USAID	6,551,060	67,813,102	8,164,740
CDC	8,813,953	NA	NA
NIH	112,844,319	643,838,823	104,810,620
DOD	\$0	24,448,940	30,518,142
TOTAL	128,209,332	736,100,865	143,493,502

Source: G-FINDER 2009.



President Obama's Global Health Initiative

- Consultation document released February 2010
- Includes MCH, HIV, TB, Malaria, NTDs, health systems, integrated solutions and a women-centered approach
- For TB, it incorporates the new USG TB strategy
- But, GHI TB targets fall far short of those in Lantos-Hyde Act

Indicator	Lantos-Hyde Target '09-'13	GHI Targets '09-'14
# new TB patients receiving treatment	4.5 million	2.6 million
# new MDR patients diagnosed, receiving treatment	90,000	57,200

Implications of FY11 Funding Request

- **50% cut in funding from language in the Lantos-Hyde Act will result in slowed progress towards scale up of TB/HIV interventions under PEPFAR.**
- **USAID will be unable to scale-up TB treatment in countries in need, especially those facing rising MDR rates.**
- **R&D funding will be inadequate to cover the costs of phase III clinical trials for new and better TB diagnostics, drugs and vaccines.**

US Advocacy for TB:



Advocacy to Control TB Internationally

ACTION is an international partnership of advocates from seven donor and high burden countries working to mobilize resources to treat and prevent the spread of tuberculosis. Specifically:

- Mobilize significant increases in new resources
- Strengthening TB within underlying policy frameworks
- Mobilize new TB financing from the World Bank for Africa

Advocacy Role: Policy advocacy to educate and engage parliamentarians/government officials through various channels such as direct advocacy, grassroots networks, creating champions, and generating media

Partnership with Stop TB

- WHO STOP TB Department & the STOP TB Partnership have been strategic partners of ACTION
- Via media, develop high level policy asks, engage key decision makers in donor countries

The RESULTS logo, featuring the word "RESULTS" in large white letters on a red background, with the tagline "the power to end poverty" in smaller white letters below it.

RESULTS
the power to end poverty

US Advocacy for TB: Infectious Diseases Society of America (IDSA)

Advocacy Priorities: Increases in funding for global TB programming and R&D for drugs, diagnostics, vaccines; Scale-up TB/HIV interventions especially in HIV clinical settings; elevate visibility/funding for TB in Administration's Global Health Initiative.

Advocacy Role: Amplify voices of US and developing country scientists in policy discussion about US investment in TB. Educate policymakers about scope of problem/scientific opportunities through issue briefs, congressional briefings, media advocacy.

Partnership with Stop TB: Member of TB/HIV core working group

Center for
Global Health Policy
Promoting Evidence-based US Action on Global HIV and Tuberculosis



US Advocacy for TB: American Thoracic Society (ATS)



Advocacy Priorities: Global & domestic TB

Advocacy Role: Direct lobbying of Congress, mobilizing clinicians & researchers, advocacy liaison for National TB Controllers Association, chair of TB legislative coalition, leadership in Stop TB USA

Partnership with Stop TB: ATS is a proactive member of the Partnership. Visits to DC from WHO and Partnership leadership are very helpful to US advocacy. ATS appreciates the invitation to participate in the Hanoi meeting and prioritization of US-based advocacy. We look forward to more such meetings. ATS recommends that WHO/Partnership have a full-time staff member in DC for coordination and technical assistance.



US Advocacy for TB: Global Health Council



Advocacy Priorities:

- Hold the USG accountable for legislative commitments made to TB
- Ensure that TB is a priority in the US global health initiative
- Advocate for increased funding for TB

Advocacy Role:

- Global Tuberculosis Roundtable
- Convene members and USG
- Raise the profile of TB

Partnership with Stop TB:

- Host meetings with Stop TB in Washington, DC
- Stop TB Advocacy Network
- World TB Day and Report Launches



US Advocacy for TB: New Tools Groups



Advocacy Priorities:

- Revising the GHI to include greater emphasis on the role of USAID in supporting R&D
- Obtaining the full funding level for USAID's cooperative agreement with the TB Alliance and first-time funding for vaccine research

Advocacy Role:

- Direct lobbying of Congress

Partnership with Stop TB:

- Stop TB and Partnership and Department highlight the importance of TB research
- Visits by Dr. Espinal and Craig David to partner field site in South Africa were wonderful opportunities to highlight the work of the South African TB Vaccine Initiative, where four vaccines are being tested



Recommendations to Strengthen Stop TB's Role in US Advocacy

Strategy & Coordination

- **Develop an overall outreach and advocacy strategy that leverages each advocacy partner's expertise**
- **Leverage the strengths of the Partnership and Coordinating Board members to influence US policymakers**
- **Map and coordinate key events and opportunities in US with advocacy partners (e.g., Lancet Series, UNGASS, IDSA journal supplement)**
- **Increasingly engage US advocacy partners in planning and participating in global advocacy events/initiatives**
- **Educate and expand us based organizations engaged in global health to increase focus on TB**

Recommendations to Strengthen Stop TB's Role in US Advocacy

Communications

Develop and support an overall US communications strategy targeting US policymakers and influencers with includes:

- Media support for key events (i.e. Lancet series launch)
- Training and strategic deployment of TB spokespeople with influence and recognition with a US audience.
- Perception testing and message platform development, including framing of TB interventions in the context of US policy priorities (i.e. women and girls).
- Development and dissemination of materials, including PowerPoint slides, fact sheets, data, and graphs/figures on the US role in TB for use by US advocacy partners.

Recommendations to Strengthen Stop TB's Role in US Advocacy

Leadership

- **Develop a year-long advocacy plan for engaging WHO and Stop TB Leadership in key advocacy efforts.**
- **Organize and bring high-level Stop TB Board members and TB spokespeople to Capitol Hill for a series of high level meetings with Congressional Committee Chairs, heads of US agencies, White House Officials.**
- **Continue participation by WHO and Partnership staff in US meetings that reach a policy audience (i.e. regular meetings with the TB Roundtable).**
- **Hold an upcoming Coordinating Board meeting in Washington, DC.**

Recommendations to Strengthen Stop TB's Role in US Advocacy

Resources recommended

- DC staff to serve as liaison between members, Stop TB, and other key global policy stakeholders
- Communications firm support for strategy development including events, media coaching, and outreach to high level influencers
- Costs associated with a board member delegation to the US and related events